Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection  
        A phase I/II trial of NOX66 in combination with nivolumab in patients with advanced cancer  
        CRO-67 is a Novel Therapeutic for Pancreatic Cancer: Implications for Tumour and Stromal Reprogramming  
        Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.  

    Read More here.

        Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors  

    Read More here.

        The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.  

    177 Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine

        Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides  
        Poster presented at 2020 Annual Meeting of the Clinical Oncology Society of Australia (COSA), “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma  
        Publication in international journal (European Urology Oncology) strengthens case for Veyonda as a safe and possibly life-prolonging treatment in late-stage prostate cancer  
        Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists  
        LuPIN Data Being Presented To Conference  
        DARRT-1 Interim Data Presented To Conference  
        Abstract first published in the Journal of Nuclear Medicine. Interim results of the LuPIN trial. Oral presentation at the Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, June 2019 Anaheim CA  
        Trial in Progress: NOX66 in combination with Palliative Radiotherapy in patients with CRPC – a Phase 1 safety and dose finding study  

    Poster at COSA Annual Meeting Perth November 2018

        A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  

    Poster at COSA Annual Meeting Perth November 2018

        NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer- A Phase 1b Proof of Concept and Dose Confirmation Study  

    Poster presented at Australian and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group Annual Scientific Meeting, Sydney. July 8-10 2018

        A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours  
        NOX66 Plus Low Dose Carboplatin CEP-1 Study Interim Trial Results  
        NOX66 Plus Carboplatin - Phase 1 Signalling Study  
        Trial Design: Safety of NOX66 in Combination with Palliative Dose Radiotherapy - A Phase 1 Dose Escalation Study  
        Idronoxil levels of patients receiving NOX66  
        ENOX2 levels of patients receiving NOX66  
        Chemosensitization of Carboplatin by NOX66